Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 177

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Allogeneic natural killer cells for refractory lymphoma

Open access
Bachanova, Veronika, Burns, Linda J., McKenna, David H., Curtsinger, Julie, Panoskaltsis-Mortari, Angela, Lindgren, Bruce R., Cooley, Sarah, Weisdorf, Daniel, Miller, Jeffrey S. · 2010 · Cancer Immunology, Immunotherapy

Abstract

We reported that IL-2 activated autologous NK cells can induce, but not maintain durable remissions in lymphoma patients. We hypothesized that allogeneic NK cells may overcome class I MHC-mediated inhibition of NK cell killing. In a pilot study, we evaluated infusion of haploidentical donor NK cells for antitumor efficacy. Six patients with advanced B cell non-Hodgkin lymphoma (NHL) received rituximab, cyclophosphamide, and fludarabine as immunosupression to permit homeostatic NK cell expansion, followed by CD3-depleted NK cell-enriched cell products followed by subcutaneous IL-2 administration (10 × 106 units every other day × 6 doses). At 2 months, four patients showed an objective clinical response. We observed early donor cell persistence in two patients (blood and in tumor-bearing node), but this was not detectable beyond 7 days. All patients demonstrated substantial increases in host-regulatory T cells (Treg) after NK cell and IL-2 therapy (180 ± 80 cells/µl vs. baseline: 58 ± 24 cells/µl, p = 0.04) which may have limited donor cell expansion in vivo. These findings suggest safety and feasibility of allogeneic NK cell therapy in patients with lymphoma; however host Treg and inadequate immunodepletion may contribute to a hostile milieu for NK cell survival and expansion. Cell therapy trials should incorporate novel strategies to limit Treg expansion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-010-0896-z

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 177

Metadata

Authors
Bachanova, V., Burns, L. J., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lindgren, B. R., Cooley, S., Weisdorf, D., & Miller, J. S.
Venue
Cancer Immunology, Immunotherapy
Published
2010-08-03
Volume
59
Issue
11
Pages
1739-1744
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2101914811
Cited by
177
References
2
FWCI
3.16
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Allogeneic natural killer cells for refractory lymphoma. https://app.cochat.ai/papers/10.1007/s00262-010-0896-z
The paper
Bachanova, V., Burns, L. J., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lindgren, B. R., Cooley, S., Weisdorf, D., & Miller, J. S. (2010). Allogeneic natural killer cells for refractory lymphoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-010-0896-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.